argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting
(WorldNews Netherlands)

argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting 07 Dec 2019 20:00 CET Company Name ARGENX SE ISN NL0010832176 Market Euronext Symbol ARGX argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting -argenx to receive $25 million from Janssen for achievement of enrollment milestone in first Phase 2 trial under collaboration December 7, 2019 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext &...